Regeneron Pharmaceuticals, Inc. (REGN) - Financial and Strategic SWOT Analysis Review

Date: April 26, 2016
Pages: 56
Price:
US$ 125.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: R8CF600A833EN
Leaflet:

Download PDF Leaflet

Regeneron Pharmaceuticals, Inc. (REGN) - Financial and Strategic SWOT Analysis Review
Regeneron Pharmaceuticals, Inc. (REGN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Regeneron Pharmaceuticals, Inc. (Regeneron) is a biopharmaceutical company which discovers, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. It develops pharmaceutical products for the treatment of various diseases areas, such as, inflammation and immune diseases, bone and cartilage, pain, cardiovascular diseases, cancer and angiogenesis, ophthalmology, metabolic and related diseases, muscle diseases and disorders. The company commercializes medicines for high low-density lipoprotein (LDL) cholesterol, eye diseases and a rare inflammatory condition and also develops medicines for oncology, rheumatoid arthritis (RA), asthma, atopic dermatitis, pain, and infectious diseases. It has operations in Ireland, Bermuda, the Netherlands, the US and the UK. Regeneron is headquartered in Tarrytown, NewYork, the US.

Regeneron Pharmaceuticals, Inc. Key Recent Developments

Apr 11, 2016: Aeras to Join the Human Vaccines Project to Accelerate Global Disease Prevention and Control
Feb 09, 2016: Regeneron Reports Fourth Quarter and Full Year 2015 Financial and Operating Results
Feb 02, 2016: Kymab Succeeds in Revoking Regeneron’s UK VelocImmune Patents
Dec 27, 2015: Regeneron Mourns Passing of Dr. Alfred G. Gilman, Board Member and Nobel Laureate
Dec 22, 2015: Prime Therapeutics prefers both cholesterol lowering drugs Praluent and Repatha on its national drug list

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers. - The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

    Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

    Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

    Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

    Note: Some sections may be missing if data is unavailable for the company
  • SECTION 1 - ABOUT THE COMPANY

    Regeneron Pharmaceuticals, Inc. - Key Facts
    Regeneron Pharmaceuticals, Inc. - Key Employees
    Regeneron Pharmaceuticals, Inc. - Key Employee Biographies
    Regeneron Pharmaceuticals, Inc. - Major Products and Services
    Regeneron Pharmaceuticals, Inc. - History
    Regeneron Pharmaceuticals, Inc. - Company Statement
    Regeneron Pharmaceuticals, Inc. - Locations And Subsidiaries
    Head Office
    Other Locations & Subsidiaries
    Regeneron Pharmaceuticals, Inc. - Key Manufacturing Facilities

    SECTION 2 – COMPANY ANALYSIS

    Regeneron Pharmaceuticals, Inc. - Business Description
    Regeneron Pharmaceuticals, Inc. - Corporate Strategy
    Regeneron Pharmaceuticals, Inc. - SWOT Analysis
    SWOT Analysis - Overview
    Regeneron Pharmaceuticals, Inc. - Strengths
    Strength - Lead Product – EYLEA
    Strength - Research and Development Activities
    Regeneron Pharmaceuticals, Inc. - Weaknesses
    Weakness - Patent Infringement Concerns
    Weakness - Discontinued Projects
    Regeneron Pharmaceuticals, Inc. - Opportunities
    Opportunity - Product Approvals
    Opportunity - Strategic Agreements
    Opportunity - Product Pipeline
    Opportunity - Strategic Partnerships
    Regeneron Pharmaceuticals, Inc. - Threats
    Threat - Competitive Pressures
    Threat - Government Regulations
    Threat - Limited Customer Base
    Regeneron Pharmaceuticals, Inc. - Key Competitors

    SECTION 3 – COMPANY FINANCIAL RATIOS

    Financial Ratios - Capital Market Ratios
    Financial Ratios - Annual Ratios
    Performance Chart
    Financial Performance
    Financial Ratios - Interim Ratios
    Financial Ratios - Ratio Charts

    SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

    Regeneron Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
    Regeneron Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016
    Regeneron Pharmaceuticals, Inc., Recent Deals Summary

    SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

    Apr 11, 2016: Aeras to Join the Human Vaccines Project to Accelerate Global Disease Prevention and Control
    Feb 09, 2016: Regeneron Reports Fourth Quarter and Full Year 2015 Financial and Operating Results
    Feb 02, 2016: Kymab Succeeds in Revoking Regeneron’s UK VelocImmune Patents
    Dec 27, 2015: Regeneron Mourns Passing of Dr. Alfred G. Gilman, Board Member and Nobel Laureate
    Dec 22, 2015: Prime Therapeutics prefers both cholesterol lowering drugs Praluent and Repatha on its national drug list
    Nov 12, 2015: Governor Cuomo Also Announces $5 Million for New Statewide Venture Capital Business Competition to Support Bio-Science & Technology Startups
    Nov 04, 2015: Regeneron Reports Third Quarter 2015 Financial and Operating Results
    Nov 03, 2015: Merus announces final Ruling in inequitable conduct case against Regeneron
    Oct 19, 2015: Regeneron Announces an Additional $350 Million Investment and 200 New Jobs in Limerick by End - 2017
    Oct 19, 2015: Regeneron Announces an Additional $350 Million Investment and 200 New Jobs in Limerick by End - 2017

    SECTION 6 – APPENDIX

    Methodology
    Ratio Definitions
    About GlobalData
    Contact Us
    Disclaimer

    LIST OF TABLES

    Regeneron Pharmaceuticals, Inc., Key Facts
    Regeneron Pharmaceuticals, Inc., Key Employees
    Regeneron Pharmaceuticals, Inc., Key Employee Biographies
    Regeneron Pharmaceuticals, Inc., Major Products and Services
    Regeneron Pharmaceuticals, Inc., History
    Regeneron Pharmaceuticals, Inc., Other Locations
    Regeneron Pharmaceuticals, Inc., Subsidiaries
    Regeneron Pharmaceuticals, Inc., Key Manufacturing Facilities
    Regeneron Pharmaceuticals, Inc., Key Competitors
    Regeneron Pharmaceuticals, Inc., Ratios based on current share price
    Regeneron Pharmaceuticals, Inc., Annual Ratios
    Regeneron Pharmaceuticals, Inc., Interim Ratios
    Regeneron Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
    Regeneron Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016
    Regeneron Pharmaceuticals, Inc., Recent Deals Summary
    Currency Codes
    Capital Market Ratios
    Equity Ratios
    Profitability Ratios
    Cost Ratios
    Liquidity Ratios
    Leverage Ratios
    Efficiency Ratios

    LIST OF FIGURES

    Regeneron Pharmaceuticals, Inc., Performance Chart (2011 - 2015)
    Regeneron Pharmaceuticals, Inc., Ratio Charts
    Regeneron Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
    Regeneron Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016
    Skip to top


    Ask Your Question

    Regeneron Pharmaceuticals, Inc. (REGN) - Financial and Strategic SWOT Analysis Review
    Company name*:
    Contact person*:
    Phone/fax*:
    Email*:
    Request invoice
    Your enquiry:
    Please click on a Check Box below to confirm you are not a robot: